Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 0
+0.34%+1.12%+34.75%+61.06% 64.38B
-0.17%+2.66%+14.32%+83.58% 56.16B
+1.06%+2.50%+15.97%+107.90% 54.16B
-1.43%-1.17%+26.27%+52.86% 45.33B
-0.48%-2.80%+18.01%+117.99% 42.25B
+0.82%+1.37%+227.94%+922.41% 40.78B
+0.75%+44.44%+107.61%+91.81% 33.8B
-0.26%-2.57%+12.55%+45.18% 32.25B
-1.29%-2.88%+21.60%-11.92% 23.57B
Average -0.06%+4.50%+53.23%+163.43% 43.63B
Weighted average by Cap. +0.02%+3.60%+50.18%+162.34%
Logo Thallion Pharmaceuticals Inc.
Thallion Pharmaceuticals Inc is a Canada-based biotechnology company. The Company develops pharmaceutical products in the areas of infectious disease and oncology. Thallion Pharmaceuticals Inc's lead clinical program, Shigamabs, is a dual antibody product for the treatment of Shiga toxin-producing E. coli bacterial infections and has completed a Phase II clinical trial. The Company is a subsidiary of BELLUS Health.
Employees
-